A Telenti

发表

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.

S M Marcovina, A. Telenti, V. Mooser, 1999, Circulation.

Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

A. Telenti, M. Battegay, H. Furrer, 1999, Journal of acquired immune deficiency syndromes.

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.

A. Telenti, P. Sudre, P Sudre, 2000, AIDS research and human retroviruses.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

M Egger, A. Telenti, P. Francioli, 1999, JAMA.

Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations

A. Telenti, W. Jacobs, J. Musser, 1997, Antimicrobial agents and chemotherapy.

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance

J P Bru, A. Telenti, M. Battegay, 2001, AIDS.

Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals

A. Telenti, T. Buclin, J. Biollaz, 2009, Clinical pharmacology and therapeutics.

The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein

A. Telenti, W. Jacobs, M. Southworth, 1997, Journal of bacteriology.

Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals

M Schwab, A. Telenti, H. Günthard, 2007, Clinical pharmacology and therapeutics.

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

A. Telenti, S. Cole, P. Imboden, 1993, The Lancet.